m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00271)
Target Name Hepatoma-derived growth factor (HDGF)
Synonyms
HDGF; High mobility group protein 1-like 2; HMG-1L2; HMG1L2
    Click to Show/Hide
Gene Name HDGF
Chromosomal Location 1q23.1
Family HDGF family
Function
[Isoform 1]: Acts as a transcriptional repressor. Has mitogenic activity for fibroblasts. Heparin-binding protein. [Isoform 2]: Does not have mitogenic activity for fibroblasts. Does not bind heparin. [Isoform 3]: Has mitogenic activity for fibroblasts. Heparin-binding protein.
    Click to Show/Hide
Gene ID 3068
Uniprot ID
HDGF_HUMAN
HGNC ID
HGNC:4856
Ensembl Gene ID
ENSG00000143321
KEGG ID
hsa:3068
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
HDGF can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line LX2 cell line Homo sapiens
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
 GSE207909
Regulation
logFC: -6.20E-01
p-value: 6.85E-14
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between HDGF and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 1.03E+00 GSE60213
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Elevated METTL3 expression promotes tumour angiogenesis and glycolysis in Gastric cancer. P300-mediated H3K27 acetylation activation in the promoter of METTL3 induced METTL3 transcription, which stimulated m6A modification of Hepatoma-derived growth factor (HDGF) mRNA, and the m6A reader IGF2BP3 then directly recognised and bound to the m6A site on HDGF mRNA and enhanced HDGF mRNA stability.
Target Regulation Up regulation
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Pathway Response Glycolysis / Gluconeogenesis hsa00010
Cell Process Glycolysis
In-vitro Model HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
NCI-N87 Gastric tubular adenocarcinoma Homo sapiens CVCL_1603
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
In-vivo Model Mice 8 weeks after splenic portal vein injection of BGC823 cells with METTL3 overexpression or vector-transfected cells.
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) [READER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by IGF2BP3
Cell Line ES-2 cell line Homo sapiens
Treatment: siIGF2BP3 ES-2 cells
Control: siControl ES-2 cells
 GSE109604
Regulation
logFC: -6.81E-01
p-value: 1.47E-02
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Elevated METTL3 expression promotes tumour angiogenesis and glycolysis in Gastric cancer. P300-mediated H3K27 acetylation activation in the promoter of METTL3 induced METTL3 transcription, which stimulated m6A modification of Hepatoma-derived growth factor (HDGF) mRNA, and the m6A reader IGF2BP3 then directly recognised and bound to the m6A site on HDGF mRNA and enhanced HDGF mRNA stability.
Target Regulation Up regulation
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Pathway Response Glycolysis / Gluconeogenesis hsa00010
Cell Process Glycolysis
In-vitro Model HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
NCI-N87 Gastric tubular adenocarcinoma Homo sapiens CVCL_1603
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
In-vivo Model Mice 8 weeks after splenic portal vein injection of BGC823 cells with METTL3 overexpression or vector-transfected cells.
Gastric cancer [ICD-11: 2B72]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Elevated METTL3 expression promotes tumour angiogenesis and glycolysis in Gastric cancer. P300-mediated H3K27 acetylation activation in the promoter of METTL3 induced METTL3 transcription, which stimulated m6A modification of Hepatoma-derived growth factor (HDGF) mRNA, and the m6A reader IGF2BP3 then directly recognised and bound to the m6A site on HDGF mRNA and enhanced HDGF mRNA stability.
Responsed Disease Gastric cancer [ICD-11: 2B72]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Glycolysis / Gluconeogenesis hsa00010
Cell Process Glycolysis
In-vitro Model HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
NCI-N87 Gastric tubular adenocarcinoma Homo sapiens CVCL_1603
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
In-vivo Model Mice 8 weeks after splenic portal vein injection of BGC823 cells with METTL3 overexpression or vector-transfected cells.
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary Elevated METTL3 expression promotes tumour angiogenesis and glycolysis in Gastric cancer. P300-mediated H3K27 acetylation activation in the promoter of METTL3 induced METTL3 transcription, which stimulated m6A modification of Hepatoma-derived growth factor (HDGF) mRNA, and the m6A reader IGF2BP3 then directly recognised and bound to the m6A site on HDGF mRNA and enhanced HDGF mRNA stability.
Responsed Disease Gastric cancer [ICD-11: 2B72]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Glycolysis / Gluconeogenesis hsa00010
Cell Process Glycolysis
In-vitro Model HGC-27 Gastric carcinoma Homo sapiens CVCL_1279
NCI-N87 Gastric tubular adenocarcinoma Homo sapiens CVCL_1603
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
In-vivo Model Mice 8 weeks after splenic portal vein injection of BGC823 cells with METTL3 overexpression or vector-transfected cells.
References
Ref 1 METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020 Jul;69(7):1193-1205. doi: 10.1136/gutjnl-2019-319639. Epub 2019 Oct 3.